Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

.

Questcor Pharmaceuticals

(

QCOR

) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.7%. By the end of trading, Questcor Pharmaceuticals fell 41 cents (-2.3%) to $17.83 on average volume. Throughout the day, 7.1 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 5.1 million shares. The stock ranged in price between $17.25-$18.50 after having opened the day at $18.20 as compared to the previous trading day's close of $18.24. Other companies within the Drugs industry that declined today were:

Peregrine Pharmaceuticals

(

PPHM

), down 33.1%,

Cardiome Pharma Corporation

(

CRME

), down 16.2%,

Cormedix

(

CRMD

), down 13.4%, and

Hemispherx Biopharma

(

HEB

), down 10.5%.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $1.15 billion and is part of the

health care

sector. The company has a P/E ratio of 9.4, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 53.6% year to date as of the close of trading on Wednesday. Currently there are five analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,

AspenBio Pharma

(

TheStreet Recommends

APPY

), up 48.9%,

China Pharma

(

CPHI

), up 12.3%,

Tianyin Pharmaceutical

(

TPI

), up 12%, and

CHINA NUOKANG BIO-PHARMACEUTICAL

(

NKBP

), up 10.5%, were all gainers within the drugs industry with

AstraZeneca

(

AZN

) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now

.

null